Skip To Main Content
Jonatan Barrera‐Chimal on Muck Rack

Jonatan Barrera‐Chimal

As seen in: Color Research & Application
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jonatan

Contact Jonatan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets

|
By Jonatan Barrera‐Chimal, Frédéric Jaisser MD, Thomas MC
| Color Research & Application Verified
Abstract Diabetic kidney disease (DKD) is the primary cause of chronic kidney disease around the globe and is one of the main complications in patients with type 1 and 2 diabetes. The standard treatment for DKD is drugs controlling hyperglycemia and high blood pressure.
Open in Who Shared Issue with article?

Short‐ and long‐term administration of the non‐steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome‐related cardio‐renal dysfunction - Lachaux - - Diabetes, Obesity and Metabolism - Wiley Online Library

|
By Normandie Univ, Lionel Nicol, Marianne Lachaux, Jonatan Barrera‐Chimal
| Color Research & Application Verified
Pathophysiological mineralocorticoid receptor (MR) activation plays a key role progression of end‐organ damage observed in cardio‐renal diseases such as metabolic syndrome. While steroidal MR antagonists improve cardiac dysfunction, it is unknown whether finerenone, a non‐steroidal MR antagonist, opposes metabolic syndrome related end‐organ, i.e. cardiac, damage.
Open in Who Shared Issue with article?
See all 2 articles